Thrombotic thrombocytopenic purpura (TTP) is a life-threatening disease that presents with thrombocytopenia, disseminated thrombosis, haemolytic anemia and organ dysfunction. The etiology of TTP has revealed that patients share a deficiency in plasma protease ADAMTS13, the enzyme responsible for cleaving ultra-large von Willebrand factor (VWF) multimers into non-thrombogenic fragments. Therefore, existing TTP mouse models were developed by targeted disruption of the ADAMTS13 gene. ADAMTS13 -/mice are mostly asymptomatic in the absence of a trigger, as redundant proteases appear to take on VWF processing. As an alternative approach to creating one such model, we have devised a strategy based on the expression of a cleavage resistant VWF mutant in mice. The creation of a disulfide bond within the A2 domain of VWF was found to render VWF multimers resistant to proteolysis by plasma proteases under flow. Furthermore, mice expressing the mVWF/p.S1494C-p.A1534C mutant present with symptoms characteristics of acute TTP such as thrombocytopenia, red cell shredding, accumulation of VWF-rich thrombi in the microvasculature and advanced TTP symptoms such as renal dysfunction and splenomegaly. Because this model appears to faithfully emulate the pathophysiology of TTP, it should prove most useful in the study of microangiopathic diseases and their treatment.
Introduction
Thrombotic thrombocytopenic purpura (TTP) is a rarely occurring human disease with a high mortality rate when left untreated (90%). TTP is due to a deficiency in plasma protease ADAMTS13 (A disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) whose sole known substrate is von Willebrand factor (VWF) 1, 2 . VWF is a large multi-domain plasma protein produced by endothelial cells and megakaryocytes in the form of ultra-large pro-thrombotic multimers (UL-VWF). In the absence of ADAMTS13, UL-VWF multimers remain uncleaved and form long endothelium-tethered "strings" that capture and cause platelets to form large aggregates in conditions of high shear rate 3 . These disseminated thrombi can accumulate in the microvasculature and cause organs to fail 4 . TTP is clinically defined as a combination of thrombocytopenia, hemolytic anemia and organ dysfunction (kidneys and brain in particular) due to the presence of VWF-rich thrombi in their venulae and arterioles 5 . One of the reasons why our understanding of TTP remains fragmentary, is the absence of an animal model of early and late stage TTP. A number of research teams have produced murine and primate models of TTP, with various degrees of success 6 . Of note, ADAMTS13deficient mice do not spontaneously develop TTP 7 , or only sporadically 8 suggesting that the cleavage of UL-VWF multimers may involve more than one enzyme in mice. In order to circumvent the challenges of a multi-proteases-targeted approach to creating a mouse model of TTP, we have opted for a simpler strategy and developed a cleavage-resistant VWF variant. Because VWF cleavage by ADAMTS13 requires the unfolding of its A2 domain by blood flow forces 9, 10 , we hypothesized that a For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From strategically placed disulfide bridge within A2 may render VWF resistant to elongational forces and proteolysis. The studies presented hereafter show that the expression of one such structurally constrained VWF mutant can elicit a rapid onset of acute TTP in mice.
Methods
A comprehensive account of all cloning, staining, biochemical procedures has been included in the supplementary data. All experiments were performed in strict compliance with Kyoto University guidelines on recombinant DNA experiments and animal experiments, as well as the regulations of the Ministry of Environment, the Ministry of Education, Culture, Sports, Science and Technology, the Ministry of Finance, Ministry of Health, Labour and Welfare, Ministry of Agriculture, Forestry and Fisheries of Japan, Ministry of Economy, Trade and Industry and the Ministry of the Environment. This study was conducted in accordance with the Declaration of Helsinki.
Reagents:
Unless stated otherwise all reagents and chemicals were manufactured by Nacalai Tesque (Kyoto, Japan). All secondary antibodies were purchased from Jackson Immunoresearch (West Grove, PA).
Determination of mVWF levels by ELISA:
Plasma VWF concentrations are measured as described previously 11 . Plasma VWF levels from normal C57Bl/6 mice was used as reference and values are expressed as a percentage of (measured VWF)/(reference VWF). Concentrated supernatant containing VWF/WT or VWF/p.S1494C-p.S1534C were used in the nanobody AU/VWFa-11-based assay to test their GpIb-binding conformation 12 .
Flow assay:
Day 1: HA-HRH1 HEK293T are plated on poly-L-lysine-coated I 0.4 Luer µ-slides (Ibidi, Martinsried, Germany) at a density of 10 5 cells/ml in complete DMEM. Day 2: cells are transfected with pCMV6-XL5-VWF constructs ( Table 1) . Day 3: complete DMEM is added to the cells. On the day of the experiment, cells are histaminetreated and washed one time with complete DMEM. Two blood samples are collected from a healthy volunteer donor. One sample is anti-coagulated with 6x ACD (65 mM trisodium citrate, 70 mM citric acid, 100 mM dextrose, pH = 4.4), the second sample with 150 U/ml heparin (heparin does not interfere with VWF cleavage by ADAMTS13 and may even increase it 13 ). Plasma-free blood is prepared from the ACD-anticoagulated sample and resuspended in 50 g/L BSA Hepes-Tyrode's buffer as described in Savage et al. 14 . Both plasma-free and heparinized blood samples are then labeled with 10 µM mepacrine for 30 min at 37˙C. I 0.4 Luer µ-slide chambers are connected to a PHD4400 syringe pump (Harvard Apparatus, Holliston, MA) equipped with a 100 ml syringe. For each chamber, 50 ml plasma-free blood is first flown in to locate platelet-decorated VWF strings. VWF strings resistance to flow-induced cleavage is then assessed in 50 ml heparinized whole blood at shear rates of 1,500 s -1 and 2,500 s -1 . For each slide, 20 VWF string-containing fields were selected and monitored (through the use of a programmable stage).
Hydrodynamic injection:
Tail vein injections were performed as described previously 16 . Briefly, mice were injected with 20-100 µg plasmid DNA in 154 mM NaCl (10% v/w ratio). Two and a half to three milliliters syringes fitted with a 26½-gauge needle were used. Injections were performed in 5 seconds or less. Mice were included in the study that expressed 
Results

Von Willebrand factor mutants (Table 1)
In order to create a proteolysis-resistant von Willebrand factor (VWF) variant, a number of cysteine codons were inserted in the A2 region of the VWF cDNA. Various positions were assessed using the Swiss-Pdb viewer software and residues predicted to be stereochemically optimal for the formation of internal cross-links were systematically mutated. Serine 1494 and serine 1534 were among the residues selected for cysteine substitution, with the intent of forming a disulfide bond between the N-terminal ends of the β1 and β2 strands of the A2 domain of VWF (mutant VWF/p.S1494C-p.S1534C) ( Fig. 3A ). Two control mutants bearing a single mutation were also engineered (mutants VWF/p.S1494C and VWF/p.S1534C).
HA-HRH1 HEK293T cells as a model for von Willebrand factor synthesis and secretion
A HEK293T cell line that stably expresses the human histamine receptor 1 was established (HA-HRH1 HEK293T). Transient transfection of VWF constructs in these cells leads to the formation of many Weibel-Palade bodies-like secretion granules ( Fig. 1A) . Upon histamine treatment, HA-HRH1 HEK293T cells secrete these granules and VWF multimers accumulate in dot-like surface microdomains similar to the ones observed in human umbilical vein endothelial cells 17 (Fig. 1A) . SDS-agarose gel electrophoresis analysis of the supernatant of these cells confirmed the presence of various VWF protein multimers ( Fig. 1B) . No difference in packaging and secretion was observed between native (WT) and mutant VWF. Moreover, VWF/WT and mutants were all produced as multimerized proteins ( Fig. 1 ).
Human VWF/p.S1494C-p.S1534C is resilient to cleavage by plasma proteases under flow and highly pro-thrombotic A flow-based experimental model was used to assess whether serine-to-cysteine VWF mutants are indeed impervious to the catalytic activity of blood proteases. HA-HRH1 HEK293T are grown and transfected inside poly-L-lysine-coated I 0.4 Luer µ-slides and subjected to histamine treatment. Cells are then exposed to a plasma-free blood cell suspension (no plasma protein) at a shear rate of 1,500 s -1 in order to trigger the unfurling of ultra-large VWF multimers from the cell surface, without cleavage. Once platelet-decorated ultra-large VWF multimers (UL-VWF) have been located in the chamber, video recording starts and whole blood (plasma proteases included) is then flown into the chamber at shear rates of 1,500 s -1 and 2,500 s -1 . As expected, UL-VWF strings from control cells are systematically severed, within seconds (VWF/WT: 106 strings analyzed, VWF/p.S1494C: 68 strings analyzed, and VWF/p.S1534C: 61 strings analyzed) ( Fig. 2A&B and online supplemental videos). UL-VWF multimers bearing the p.S1494C-p.S1534C mutations (93 and 41 strings analyzed at 1,500 s -1 and 2,500 s -1 respectively), on the contrary, do not undergo cleavage (observation period: 5 min at 1500 s -1 , 2.5 min at 2500 s -1 ( Fig. 2A&B and online supplemental videos). The double mutant was found to support the formation of unexpectedly large platelet aggregates. These platelet aggregates appear to initially distribute at somewhat regular intervals along the string axis instead of forming a continuous thrombus. We considered the possibility that the S1494C-S1534C double For personal use only. on November 16, 2017. by guest www.bloodjournal.org From mutation induced an active VWD-type 2B-like conformation of the protein, thereby promoting platelet binding. However, mutant VWF/p.S1494C-p.S1534C proved similar as VWF/WT in binding to nanobody AU/VWFa-11 (activation factor-ratio mutant/WT 0.84±0.33; n=5), where for positive control type 2B mutant VWF/p.R1306Q this ratio was 18±8 (n=3)(data not shown). Thus, the higher plateletbinding potential of the double mutant does not originate from an intrinsically more active conformation than VWF/WT, but rather may be due to an increased sensitivity to shear stress-induced exposure of the A1 domain.
Cysteines 1494 and 1534 form a disulfide bridge that renders VWF A2 resistant to proteolysis in vitro
We have hypothesized that substituting cysteine residues to Ser1494 and Ser1534 would result in the formation of a novel disulfide bond within the A2 domain of VWF (which already contains a vicinal disulfide bond at C1669-C1670). Within the A2 domain, the β1-strand interfaces directly with the cleavage site on the β4-strand 18 . In theory, this bond would prevent the unfolding of the β1-α1 loop and prevent proteases from accessing the cleavage site ( Fig. 3A) . In order to demonstrate that such a disulfide bond had formed, recombinant A2/WT and A2/p.S1494C-p.S1534C proteins were generated and subjected to sulfhydryl group labeling by Oregon green 488-maleimide after reduction by β-mercaptoethanol. As expected untreated A2/WT and A2/p.S1494C-p.S1534C showed no detectable Oregon green 488-maleimide labeling thus confirming the absence of free thiol groups in these proteins. Reduced A2/WT was found to incorporate significant amount of Oregon green 488-maleimide, which can only be attributed to newly formed sulfhydryl groups on cysteines 1669 and 1670. Reduced A2/p.S1494C-S1534C was found to incorporate ~ 2 times as much Oregon green 488-maleimide than A2/WT does (mean ±SE: 0.512 ±0.077 and 1.23 ±0.351 respectively), thus confirming that twice as many sulfhydryl groups had become exposed ( Fig. 3B ). These results unequivocally show that the sulfhydryl goups on all four cysteine residues in A2/p.S1494C-p.S1534C are oxidized and form two disulfide bridges. In order to demonstrate that the newly formed C1494-C1534 disulfide bond confers protease resistance to the host domain, recombinant A2/WT and A2/p.S1494Cp.S1534C proteins were subjected to plasma protease treatment in the absence or presence of a reducing agent. While no difference was observed in the rate of proteolysis of both native and reduced A2/WT, cleavage of A2/p.S1494C-p.S1534C could only be achieved through β-mercaptoethanol treatment (Fig. 3C) . Similarly, while almost complete degradation of A2/WT could be achieved after overnight trypsin treatment, only limited A2/p.S1494C-p.S1534C proteolysis could be observed under the same condition (p = 0.0000382) ( Fig. 3D ). Taken together, these findings show that a novel disulfide bond has formed between Cys1494 and Cys1534 and that it renders the A2 domain of VWF resistant to proteolysis by plasma proteases and trypsin as well.
Hydrodynamic injection of pLIVE-m VWF/p.S1494C-p.A1534C constructs causes mice to develop thrombocytopenia and schistocytes
For in vivo analysis, we subsequently focused on the VWF/p.S1494C-p.S1534C double mutant (mVWF/p.S1494C-A1534C for murine VWF), as the single mutations display behavior similar to VWF/WT in the in vitro assays. VWF/WT and the double mutant were expressed via hydrodynamic gene transfer in VWF-deficient mice. Blood samples were collected 4 and 7 days after injection, and analyzed for VWF antigen, platelet counts and multimeric pattern. In accordance with our previous in vivo studies involving hydrodynamic injectionmediated expression of VWF, mice were included expressing VWF antigen levels between 300 and 1000% 16, 19, 20 . At both 4 and 7 days post-injection, antigen levels were similar for mVWF/WT and mVWF/p.S1494C-p.A1534C. At day 4, antigen levels were 688±208% (mean±SD; n=6) and 697±302% (n=7; unpaired t-test: p>0.05) for mVWF/WT and mVWF/p.S1494C-p.A1534C, respectively. At day 7, antigen levels were 553±234% (n=6) and 660±212% (n=7; p>0.05) for mVWF/WT and mVWF/p.S1494C-p.A1534C, respectively. Multimer analysis revealed that for mVWF/WT the full range of multimers was present, both at day 4 and day 7 (Fig. 4A) . A more extended range of multimers was present for mice expressing mutant mVWF/p.S1494C-p.A1534C at both day 4 and day 7. Interestingly, the ratio HMW (11-20 bands)/LMW (1-5 bands) multimers was increased for mutant VWF (0.09 ±0.04) compared to VWF/WT (0.03 ±0.02): bands representing dimers and tetramers were more intense for VWF/WT compared to mutant VWF. This increased ratio seems compatible with the presence of VWF that is resistant against proteolytic degradation. Interestingly, Coulter platelet counts were significantly different between mVWF/WT and mVWF/p.S1494C-p.A1534C at both day 4 and day 7 after injection ( Fig. 4B ). At day 4, platelet counts were 715±107 (mean±SD; n=6) and 373±339 (n=7; p=0.0397) for mVWF/WT and mVWF/p.S1494C-p.A1534C, respectively. At day 7, platelet counts were 841±131 (n=6) and 369±277 (n=7; 0.0028) for mVWF/WT and mVWF/p.S1494C-p.A1534C, respectively. At both time points, none of the mVWF/WT-expressing mice displayed platelet counts below 600, whereas 5 out of 7 (Fisher's exact test: p=0.02) and 6 out of 7 (p=0.005) mice for mVWF/p.S1494Cp.A1534C displayed platelet counts below 450 at day 4 and 7, respectively ( Fig. 4B ). These findings show that platelet depletion keeps on occurring in the days that follow the early onset of thrombocytopenia. GIEMSA staining of blood smears taken from both mouse groups confirmed that animals expressing VWF/WT have normal platelet and red cell numbers ( Fig. 4C ). Blood smears from mice expressing the double mutant, on the other hand, reveal multiple anomalies. These blood films have fewer red cells, very few platelets and present with occasional platelet micro-aggregates and schistocytes ( Fig. 4C ). Interestingly, the extent of the thrombocytopenia seen in these animals was found to vary with the nature of the assay used to assess platelet number, with size-based particle counting of plasma samples ( Fig. 4B ) yielding higher platelet counts than GIEMSA-stained smeared blood samples do (Fig. 4C ). This discrepancy is probably due to the presence of schistocytes in the blood of these animals; red cell fragments being indistinguishable from platelets in the Coulter particle counter, they may cause platelet numbers to be over-estimated. Overall these study show that expression of mVWF/p.S1494C-p.A1534C in mice is associated with a range of blood disorders that are considered hallmarks of TTP in humans.
mVWF/p.S1494C-p.A1534C mice present with renal dysfunction
At day 4 post-injection, blood samples were collected from mice and analyzed for creatinine and blood urea nitrogen (BUN) contents ( Fig. 5A ). Mice expressing mVWF/WT have normal creatinine and BUN levels (mean = 0.084 ± 0.008 mg/dL; n=5 and mean = 21 ± 2 mg/dL; n=5 respectively). Conversely, mVWF/p.S1494Cp.A1534C mice have 5-6 fold increased creatinine (mean = 0.45 ± 0.07 mg/dL; n=5)
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From and 3-4 fold increased BUN levels (mean = 77. ± 15 mg/dL; n=5), levels that are indicative of impaired kidney functions (Fig. 5A) . In order to further investigate these findings, organs were harvested from these animals at day 4 post-injection for histological analysis. While control mice were asymptomatic, kidneys from mice expressing mVWF/p.S1494C-p.A1534C presented with widespread bruising (Supplemental Fig. 1A ). Immunostaining of frozen sections taken from these animals revealed the presence of numerous VWF-rich platelet aggregates throughout the kidney vasculature (Fig. 5B) . The apparent high VWF content of these thrombi suggests that circulating thrombogenic VWF is indeed responsible for the capture of platelets and the accumulation of thrombi in renal blood vessels. While histological analysis of brain, lung and hepatic tissues did not reveal any significant difference between control and double-mutant mice (data not shown), severe liver bruising was seen in most double VWF mutant mice (Supplemental Fig. 1B) . Lastly, half of mVWF/p.S1494C-p.A1534C mice suffered from splenomegaly (Supplemental Fig.  1C ).
Discussion
The aim of this study was the creation of a mouse model that mimics the clinical features of TTP. In order to achieve that goal, VWF mutants exhibiting various cysteine substitutions were created. Our hypothesis was that if some of the mutants were able to form disulfide bonds within the A2 domain, they would become resilient to deformation by flow forces and proteolysis by plasma proteases. A novel cell-based flow model was created with the intent of testing these VWF mutants in a context as physiologically relevant as possible. As reported elsewhere 21 , HEK293T cells have the ability to synthetize, package and secrete VWF in the form of long multimers (strings). In an attempt to further improve on that model we have created the HA-HRH1 HEK293T cell line that stably expresses the human histamine receptor 1. Histamine treatment of these cells was found to result in cell surface exposure of secreted VWF multimers in structures resembling the "VWF dots" seen in endothelial cells 17 . In order to trigger the unfurling of these VWF multimers, a novel in vitro cell flow system was designed. In this model HA-HRH1 HEK293T cells are grown in poly-L-lysine-coated flow chambers and subjected to high shear flow forces two to three days after transfection. Flow analysis is performed in two times. Cells are first exposed to a plasma-free blood cell suspension to allow the detection of UL-VWF multimers in the flow chamber in the absence of protease. Once platelet-decorated UL-VWF multimers have been identified, whole blood is injected into the flow chamber to assess the thrombogenic potential and protease susceptibility of each VWF mutant. Exposure of HEK293T cells to high shear rates revealed that cell surface-tethered VWF strings can support the formation of large platelet aggregates. In accord with previous work by Nishio et al. that showed that binding of platelet receptor GpIbα to the A1 domain of VWF facilitates A2 cleavage by ADAMTS13 13 , severance of VWF/WT, VWF/p.S1494C and VWF/p.S1534C strings was only seen after platelet binding had occurred. VWF mutants bearing the p.S1494C-p.S1534C double-substitution were found to be resilient to cleavage by plasma proteases under flow and highly thrombogenic. Analysis of recombinant A2 domains confirmed that the p.S1494C-p.S1534C mutation was conducive to the formation of a novel internal disulfide bond and that chemical reduction of this bond was required for A2/p.S1494C-p.S1534C cleavage. A Cys1494 to Cys1534 covalent bond would, in theory, prevent the dissociation of the For personal use only. on November 16, 2017. by guest www.bloodjournal.org From β1 and α1 A2 subdomains. Since the cleavage site for ADAMTS13 is located on the β4-strand 22 , a structurally constrained β1 would, in theory, prevent access to adjacent β4 binding sites (Fig. 3A ). Whether these mutations prevent proteases recruitment to VWF all together or cause a misalignment of the enzymes catalytic domains with important A2 residues remains to be determined. In the case of ADAMTS13, binding sites have been identified in and outside the A2 domain 23 . One such site includes Leu1603, located on the β4-strand. Mutation of Leu1603 was reported to block ADAMTS13 cleavage of VWF but not their association 24 . It is therefore conceivable that a β4-strand-proximal steric hindrance due to the Cys1494-Cys1534 bond would primarily affect cleavage rather than binding of the protease. Another possible mechanism through which the p.S1494C-p.S1534C double-mutation may confer cleavage resistance to VWF might involve the A2 Ca ++ binding site identified by Zhou et al. in their alternate A2 domain crystal structure. The resolved structure published by this group shows that two out the four residues forming this Ca ++ binding site are located on the β1 and β4 strands of A2 25 , it is therefore conceivable that a structurally constrained β1 would reinforce the stabilizing action Ca ++ has on the A2 domain, thereby preventing its unfolding under shear. Follow-up studies will have to be undertaken to further address these issues. In acute acquired TTP patients, symptoms are triggered by widespread thrombosis due to the presence of large uncleaved VWF multimers in the circulation. As a result, patients initially present with thrombocytopenia, VWF-rich platelet aggregates and schistocytes (due to the mechanical fragmentation of erythrocytes in partially occluded vessels). As the disease progresses they may present with enlarged spleens (splenomegaly), neurological impairment (~65% of patients), kidney dysfunction and heart failure. Vectors encoding mVWF/WT and mVWF/p.S1494C-p.A1534C were injected into mice by hydrodynamic injection in order to assess their ability to elicit TTP-like symptoms in VWF-null mice. Within 4 days of the injection, WT and mutant VWF multimers could be detected in the plasma of these mice at levels comparable to normal C57Bl/6 VWF plasma levels and up to 10 times higher. The presence of small size VWF multimers in the plasma of mVWF/p.S1494Cp.A1534C-expressing animals suggests that proteases other than ADAMTS13 can take on the processing of VWF, an observation that echoes previous findings by other groups 6, 7, 26 . A number of candidate proteases capable of cleaving VWF have been identified, such as cytotoxic lymphocyte T and natural killer cell-secreted granzyme B and M 27, 28 , and leukocyte-derived cathepsin G, elastase, matrix metalloproteinase 9 (MMP9) and plasmin 22, 29 . While elastase, MMP9 and cathepsin G have been shown to have either identical or proximal cleavage sites to ADAMTS13, plasmin, granzyme B and M appear to cleave VWF at more distant sites. The relevance of alternative proteases in regulating VWF multimer size has recently been demonstrated in an elegant study by Tersteeg et al. 30 , revealing that plasmin can function as a back-up system in the absence of ADAMTS13. For the present study, we have not yet tested other proteases with regard to the ADAMTS13-resistant double mutant. However, given the notion that leukocyte-derived proteases cleave VWF within the similar A2domain region as ADAMTS13, we anticipate that the double mutant will be resistant against proteolysis by these proteases as well. This issue will be subject of investigation in future studies by our group.
Interestingly, mVWF/p.S1494C-p.A1534C was found to preferentially form higher molecular weight multimers whereas lower molecular size multimers were observed for mVWF/WT. Even at day 7, mice expressing mutant mVWF did have HMWmultimers, despite the presence of strongly reduced platelet counts (less than 300x10 3 /µl). Previously, it has been reported that there is a frequent loss of HMWmultimers with acute TTP 31 , a phenomenon that is not reproduced in our mouse model. One explanation for this apparent discordance could be that the amount of HMW-VWF that is consumed into VWF-platelet aggregates is relatively small compared to the amount of circulating VWF, and hence escapes detection via multimeric analysis. Unlike UL-VWF multimers which are partially in an active, platelet-binding confirmation, mVWF/p.S1494C-p.A1534C multimers proved similar to VWF/WT in binding to nanobody AU-VWFa-11, which specifically detects the active conformation present in UL-VWF or VWD-type 2B 12 . This indicates that the double mutant lacks the intrinsic potential to spontaneously interact with platelets. To explain its higher platelet binding potential in the circulation and in the in vitro perfusion assays, we can but speculate at this moment. It is known that the A2 domain plays a role in the exposure of the platelet-binding A1 domain 32 . In globular VWF, the A2 domain is in close proximity to the A1 domain, interfering with platelet access to the A1 domain. Under elevated shear stress conditions, the A2 moves away from the A1 domain, allowing platelet binding. We anticipate that the increased disulfide-bridge induced rigidity of the A2 domain promotes its moving away from the A1 domain even under low shear stress conditions. This increased platelet binding potential cannot be counteracted via ADAMTS13-mediated proteolysis. Apparently, the combination of both ADAMTS13-resistance and more shear stress-sensitive exposure of the platelet-binding site contribute to the thrombogenicity of the mutant. In any case, mice expressing murine VWF/p.S1494C-p.A1534C were found to develop symptoms very similar to the ones seen in TTP patients: presence of VWF-rich platelet aggregates in the vasculature, thrombocytopenia, red cell fragmentation, renopathy and occasional splenomegaly. Neurological and cardiac impairments were not assessed in those animals but may be occurring as well.
In conclusion, we have developed a novel model of microangiopathic disease that accurately mimics TTP symptoms and which can be used for various further investigations. First, it provides an alternative approach to existing chemically, mechanically or heat-induced in vivo thrombosis models 15, 33, 34 , allowing it to study the role of continuous platelet aggregation in the context of thrombosis and hemostasis. Furthermore, this system is based on interactions between VWF and its platelet receptor GpIb, and could therefore be used as an in vivo model to study molecular events responsible for the transition of rolling platelets into fully active, firmly adherent platelets. Also from the perspective of our understanding of thrombotic microangiopathies (TMA), our model could be of relevance. TMA is generally defined as a combination of microangiopathic haemolytic anemia, thrombocytopenia and microvascular thrombosis. The initial therapy for all TMAs is plasma exchange, an expensive, cumbersome procedure with such potential side effects as infection, cardiac arrest, venous thrombosis or hypotension. While we realize that our model is ill-suited for the study of ADAMTS13-based TTP therapies, it provides several other advantages. It could be useful for preclinical testing of therapies capable of disrupting VWF-platelet interactions, conceptually similar to ALX0081 and ARC15105 that have been tested in a clinical setting for the treatment and prevention of acute and chronic TMA. Finally, our model provides a platform to investigate effects secondary to the occlusion of vessels by VWF/platelet aggregates, in particular organ damage, neuronal aberrations and schistocyte formation. Thus, our model could be helpful in further delineating thrombotic processes and their secondary effects as well as in the development of novel therapeutic strategies in the treatment of TMA.
Constructs
Purpose
h VWF/WT Immunofluorescence/flow assay h VWF/p.S1494C h VWF/p.S1534C h VWF/p.S1494C-p.S1534C Vn SP -A2-His 6 Purification/proteolysis assays Vn SP -A2/p.S1494C-p.S1534C-His 6 pLIVE mVWF/WT Hydrodynamic injection in mice mVWF/p.S1494C-p.A1534C Table 1 : List of von Willebrand factor (VWF) constructs used in this study. Complementary DNA encoding either full-length human VWF or its A2 domain were subcloned into pCMV6-XL5, a plasmid that allowed better VWF expression in HEK293T cells than any other vector tested (data not shown). pLIVE constructs were done using the cDNA for murine VWF. Of note: murine VWF constructs bear a T103M mutation. Representative staining of transiently transfected cells with or without fixation and permeabilization. Fixed cells were co-stained for DNA (DAPI) and VWF (Alexa-Fluor 488); a large number of Weibel-Palade body-like structures can be observed throughout the cytoplasm of both wild type and all four mutant VWF-transfected cells (The data is representative of three independent experiments in which each construct was transfected in 3 x 8-well slides. A minimum of 10 microscopic fields per well were photographed for a total of > 240 fields analyzed per construct). Live histaminetreated cells were co-stained with the plasma membrane marker CellMask DeepRed (Red) and anti-VWF antibody (Alexa-Fluor 488). Von Willebrand factor-rich domains can be seen on the surface of some of the cells (magnified fields are shown in the right column). No differences were observed between wild-type and mutant VWF-expressing cells (The data is representative of three independent experiments in which each construct was transfected in 3 x 8-well slides. A minimum of 5 microscopic fields per well were photographed for a total of > 120 fields analyzed per construct). Wide field images were captured at an original magnification of 63x (1.4 aperture), high magnification images at 100x (1.4 aperture). All images were captured on a LSM 510 Meta confocal microscope. Capture of live samples was performed at 37˙C, all other samples were photographed at room temperature. Fixed samples were mounted in Vectashield mounting medium (Vector laboratories, Burlingame, CA). All images were captured and processed with the LSM 510 software. B. Samples taken from cells transfected with VWF wild type, VWF/p.S1494C, VWF/p.S1534C, VWF/p.S1494-p.S1534C were run on a 2% agarose 0.1% SDS gel. After transfer, membranes were analyzed for VWF expression. The dashed line indicates that part of the immunoblot is cropped to exclude irrelevant samples. All constructs expressed as multimerized proteins when expressed in HEK293T cells (n = 2). Figure 2 : Human von Willebrand factor p.S1494C-p.S1534C is resilient to proteolysis under flow. pCMV6-XL5-VWF-transfected HA-HRH1 HEK293T are grown inside poly-L-lysine-coated flow chambers and exposed to mepacrine-labeled whole blood at flow rates of 1,500 s -1 and 2,500 s -1 . A. Corresponding movies can be found in the online supplemental material. VWF/WT, VWF/p.S1494C or VWF/p.S1534C strings are systematically severed when exposed to whole blood at shear rates of 1,500 s -1 or above. VWF strings containing the p.S1494C-p.S1534C double-mutation are however utterly resistant to proteolysis, even at higher shear rates (2,500 s -1 ). As a result, VWF/p.S1494C-p.S1534C strings are able to support the formation of massive thrombi by capturing circulating blood platelets. (n refers to the number of individual experiments performed for each construct) B. VWF/p.S1494C-p.S1534C strings vary in length (from ~ 100 µm to > 1 mm). Reconstruction of a 420 µm string captured over multiple photographic fields, is presented as an example. C. The table summarizes the total number of VWF strings analyzed (n) for each construct. VWF/WT, VWF/p.S1494C, VWF/p.S1534C strings were found to be systematically cleaved upon exposure to plasma proteases. None of the 93 VWF/p.S1494Cp.S1534C strings analyzed at 1,500 s -1 were cleaved after up to 5 min exposure to whole blood. Similarly, no cleavage of VWF/p.S1494C-p.S1534C strings was observed at 2,500 s -1 , however out of the 44 strings observed 3 could not be included in the analysis because of the detachment of the cells they were tethered to (*).
Figure legends
Original magnification: 63x (aperture 1.4). All videos were captured on a LSM 510 Meta confocal microscope at 37˙C and processed with the LSM 510 software. Figure 3 : S1494C and S1534C form a disulfide bond that renders the A2 domain of VWF resistant to proteolysis by plasma proteases and trypsin. A. Cysteine 1494 and 1534 are projected to form a disulfide bond linking the amino-terminal ends of the β1 and β2 strands thereby making the unfolding of the β1-α1-β2 subdomain more difficult. The recombinant A2 domain used in our studies is flanked by the human vitronectin signal peptide (Vn SP ) and a carboxy-terminal His 6 tag. Cysteine 1494, and 1534 are circled, as well as cysteine 1669 and 1670 (engaged in a vicinal disulfide bridge). B. In the absence of reducing agent neither A2/WT nor A2/p.S1494C-S1534C display any Oregon green 488-maleimide labeling. However upon βmercaptoethanol (β-ME) treatment and resulting sulfhydryl moieties exposure, both A2/WT and A2/p.S1494C-S1534C show Oregon-green 488-maleimide incorporation (n = 3). In order to quantify the difference in Oregon green 488-maleimide incorporation from one sample to the other, the mean immunofluorescence intensity of each bands was quantified with the NIH ImageJ 1.41 software. The measured means for all three gels were then averaged and expressed as a fraction of the nonreduced A2/WT mean. Error bars indicate the standard error. The difference in signal (~2) accounts for the number of disulfide bonds having been reduced in the two proteins (one such bond in A2/WT, two for A2/p.S1494C-S1534C). The black and white image of the fluorescent gel was obtained through Photoshop grayscale mode adjustment and tone inversion of the original scan. The gel was subsequently stained with Coomassie blue as a loading control. C. A2/WT and A2/p.S1494C-p.S1534C were incubated with platelet-poor plasma overnight at 37˙C with or without prior β-ME and analyzed by SDS-PAGE on a 17% acrylamide gel. While A2/WT is cleaved under both conditions, A2/p.S1494C-p.S1534C is only cleaved after β-ME treatment (n = 3). D. Similarly, A2/p.S1494C-p.S1534C shows stronger resistance to trypsin digestion than A2/WT. Statistical analysis shows that 62.06 ±1.67% (mean ±SE) of A2/WT is proteolyzed by trypsin while only 4.66 ±0.84% (mean ±SE) of A2/p.S1494C-p.S1534C is degraded under the same condition. The probability associated with a student t-test is 3.82 x 10 -5 (n = 7). Figure 4 : Mice expressing murine VWF/p.S1494C-p.A1534C are thrombocytopenic and present with schistocytes. Every mouse used in this study is VWF -/-. A. Multimer analysis of plasma taken from mice expressing mVWF/p.S1494C-p.A1534C (Mouse 1 and 2) or mVWF/WT at day 4 and day 7 after hydrodynamic injection employing 2% SDS-agarose gel electrophoresis. Gels were loaded with 0.1 μg antigen per lane. All multimers originate from the same multimer gel. B. Coulter platelet counts and plasma VWF antigen ratio were measured at day 4 and 7 post-injection. Only mice with VWF antigen levels within the 300-1000% normal range were included in this study. Significant differences were found in platelet counts between mVWF/WTexpressing mice and mVWF/p.S1494C-p.A1534C-expressing mice. While mVWF/WT mice have normal platelet counts at both time points, 5 out 7 mVWF/p.S1494C-p.A1534C mice were found to be thrombocytopenic at day 4 and 6 out of 7 by day 7. C. Blood smears were prepared with heparinized blood from mice injected with normal and mutant pLIVE-mVWF constructs and subjected to GIEMSA staining. While mice expressing mVWF/WT do not present with any anomalies, mice expressing mVWF/p.S1494C-p.A1534C present with occasional platelet aggregates (black arrow), schistocytes (white arrows) and fewer platelets and erythrocytes. For each mouse, two blood smears were prepared and 5 mice well analyzed for each construct. Wide field images were captured at an original magnification of 63x (1.4 aperture), high magnification images at 100x (1.4 aperture). All images were captured on a LSM 510 Meta confocal microscope at room temperature. All images were captured and processed with the LSM 510 software. Figure 5 : Expression of mVWF/p.S1494C-p.A1534C in mice is associated with abnormal renal functions. A. Blood creatinine and blood urea nitrogen (BUN) levels were measured at day 4 post-injection (in duplicates and on 5 mice for each construct). Elevated creatinine and BUN levels in pLIVE-mVWF/p.S1494Cp.A1534C injected mice show that these animals suffer from abnormal kidney functions. Values plotted are the mean ± SE. Student t-test was performed on both sets of data. B. Histological analysis of kidneys taken from animals at day 4 postinjection. These photographs are representative of tissue staining performed on five animals per construct. No platelet staining was seen in the kidneys of mice expressing mVWF/WT. Conversely, mVWF/p.S1494C-p.A1534C-expressing mice present with numerous platelet clots in the kidney vasculature. Those clots generally co-localize with large VWF deposits. High magnification (100x) of the longitudinal view of one such vessel shows nearly complete occlusion by VWF-rich thrombi. Wide field images were captured at an original magnification of 63x (1.4 aperture), high magnification images at 100x (1.4 aperture). All images were captured on a LSM 510 Meta confocal microscope at room temperature. Samples were mounted in Vectashield mounting medium (Vector laboratories, Burlingame, CA). All images were captured and processed with the LSM 510 software.
